Veteran Advocate Urges FDA to Consider Psychedelics for Mental Health
A Marine Corps veteran and advocate pressed the FDA to consider psychedelic treatments for severe mental health conditions, as reported by MedPage Today.
MedPage Today's weekly feature, "What We Heard This Week," captured a striking plea from Marine Corps veteran Eric Jansen. Speaking as a representative of the Balanced Veterans Network, Jansen urged the FDA to consider psychedelic drugs for severe mental health conditions.
"No veteran should need a passport to find hope," Jansen said, according to the report. His comment suggests that veterans facing mental health challenges should not have to seek treatment or relief outside the United States, and it frames psychedelic therapies as a domestic policy question rather than only a clinical one.
The quote underscores the growing pressure from veteran advocates for regulators to take psychedelic treatments seriously. MedPage Today's weekly roundup platformed that call, giving it visibility in the medical community, though the report itself does not detail specific policy proposals or clinical evidence.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.